Bridging the Gaps between Fundamental, Preclinical and Clinical Research: Report from a Global HIV Vaccine Enterprise Working Group

Oregon Health and Science University, United States. Other members of the Enterprise Working Group included: Victor Appay, Universite Pierre et Marie Curie, France; Susan Barnett, Novartis, USA; Dan Barouch, Harvard Medical School, USA; Christian Brander, Fundacio irsiCaixa/HIVACAT/ICREA, Spain; David Cooper, University of New South Wales, Australia; Daniel Douek, National Institute of Allergy and Infectious Diseases, USA; Pat Fast, International AIDS Vaccine Initiative, USA; Alan Fix, National Institute of Allergy and Infectious Diseases, USA; David Goldstein, Duke University, USA; Glenda Gray, University of the Witwatersrand, South Africa; Ashley Haase, University of Minnesota, USA; Scott Hammer, Columbia University, USA; Barton F. Haynes, Duke University, USA; Michael Lederman, Case Western Reserve University, USA; Yves Levy, Universite Paris, France; Jeffrey D. Lifson, National Cancer Institute, USA; Nelson L. Michael, Military HIV Research Program, USA; Gary Nabel, National Institute of Allergy and Infectious Diseases, USA; Giuseppe Pantaleo, University of Lausanne, Switzerland; Nina Russell, Bill and Melinda Gates Foundation, USA; Rafick-Pierre Sekaly, University of Montreal, Canada; Yiming Shao, National Center for AIDS, China; Jim Tartaglia, Sanofi Pasteur, Canada. Bridging the Gaps between Fundamental, Preclinical and Clinical Research: Report from a Global HIV Vaccine Enterprise Working Group